France: AFB appoints new operating partner

Life sciences investment company Advent France Biotechnology (AFB) has appointed Geoffroy de Ribains as operating partner.

With de Ribains’ appointment, AFB said that it had strengthened its capabilities in company building and development, a key differentiating feature in the French life sciences seed investment market.

He has a wide range of expertise including financing, company building and management, strategic and business planning, and product development in the biotech, medtech and diagnostics industries.

“We are delighted to welcome Geoffroy on board. He brings a rare combination of experience as a life sciences investor and as an entrepreneur”, said co-founder and chairman Alain Huriez.

“His experience in creating and building companies that originate from academic research labs will be very useful in helping execute AFB’s strategy of seed investing in academic spin-offs,” he added.

de Ribains was previously chief executive of Step Pharma, a Paris-based biotech startup that he co-founded and brought from target discovery to preclinical candidate stage, raising €16m (US$18.8m) in equity and more than €2m in non-dilutive funding. He is also a co-founder of Biomunex Pharmaceuticals.

He brings 12 years of venture capital investing experience at Andera Partners (formerly E. de Rothschild Investment Partners) and Atlas Venture. He has been directly involved in 20 new investments, six M&A transactions and three company exits and was on the board of eight companies.